Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The deoxycytidine analog decitabine (DAC) can deplete DNA methyl-transferase 1 (DNMT1) and thereby modify cellular epigenetics, gene expression, and differentiation. However, a barrier to efficacious and accessible DNMT1-targeted therapy is cytidine deaminase, an enzyme highly expressed in the intestine and liver that rapidly metabolizes DAC into inactive uridine counterparts, severely limiting exposure time and oral bioavailability. In the present study, the effects of tetrahydrouridine (THU), a competitive inhibitor of cytidine deaminase, on the pharmacokinetics and pharmacodynamics of oral DAC were evaluated in mice and nonhuman primates. Oral administration of THU before oral DAC extended DAC absorption time and widened the concentration-time profile, increasing the exposure time for S-phase–specific depletion of DNMT1 without the high peak DAC levels that can cause DNA damage and cytotoxicity. THU also decreased interindividual variability in pharmacokinetics seen with DAC alone. One potential clinical application of DNMT1-targeted therapy is to increase fetal hemoglobin and treat hemoglobinopathy. Oral THU-DAC at a dose that would produce peak DAC concentrations of less than 0.2μM administered 2×/wk for 8 weeks to nonhuman primates was not myelotoxic, hypomethylated DNA in the γ-globin gene promoter, and produced large cumulative increases in fetal hemoglobin. Combining oral THU with oral DAC changes DAC pharmacology in a manner that may facilitate accessible noncytotoxic DNMT1-targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831
On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs
Santi, D. V., Garrett, C. E., & Barr, P. J. (1983) · Cell · doi:10.1016/0092-8674(83)90327-6 · Cited by 401
Saunthararajah, Y., Hillery, C. A., Lavelle, D., Molokie, R., Dorn, L., Bressler, L., Gavazova, S., Chen, Y.-H., Hoffman, R., & DeSimone, J. (2003) · Blood · doi:10.1182/blood-2003-05-1738 · Cited by 277
Self-citationSchermelleh, L., Haemmer, A., Spada, F., Rösing, N., Meilinger, D., Rothbauer, U., Cardoso, M. C., & Leonhardt, H. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm432 · Cited by 247
Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A.
Milhem, M., Mahmud, N., Lavelle, D., Araki, H., DeSimone, J., Saunthararajah, Y., & Hoffman, R. (2004) · Blood · doi:10.1182/blood-2003-07-2431 · Cited by 195
Self-citationNegrotto, S., Ng, K. P., Jankowska, A. M., Bodo, J., Gopalan, B., Guinta, K., Mulloy, J. C., Hsi, E., Maciejewski, J., & Saunthararajah, Y. (2012) · Leukemia · doi:10.1038/leu.2011.207 · Cited by 90
Self-citationNg, K. P., Ebrahem, Q., Negrotto, S., Mahfouz, R. Z., Link, K. A., Hu, Z., Gu, X., Advani, A., Kalaycio, M., Sobecks, R., et al. (2011) · Leukemia · doi:10.1038/leu.2011.159 · Cited by 68
Self-citationHu, Z., Negrotto, S., Gu, X., Mahfouz, R., Ng, K. P., Ebrahem, Q., Copelan, E., Singh, H., Maciejewski, J. P., & Saunthararajah, Y. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0191 · Cited by 50
Self-citation
Cited by
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies
Manwani, D., & Frenette, P. S. (2013) · Blood · doi:10.1182/blood-2013-05-498311 · Cited by 428
“A phase 1 combination study of oral decitabine with tetrahydrouridine, a competitive inhibitor of cytidine deaminase, is targeted at improved oral bioavailability of decitabine.(34) Sodium dimethylbutyrate.”
BackgroundShelton, J., Lu, X., Hollenbaugh, J. A., Cho, J. H., Amblard, F., & Schinazi, R. F. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00209 · Cited by 409
Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies
Vinjamur, D. S., Bauer, D. E., & Orkin, S. H. (2018) · British Journal of Haematology · doi:10.1111/bjh.15038 · Cited by 114
Saunthararajah, Y. (2013) · Hematology · doi:10.1182/asheducation-2013.1.511 · Cited by 79
Self-citation
Metadata
- Authors
- Lavelle, D., Vaitkus, K., Ling, Y., Ruiz, M. A., Mahfouz, R., Ng, K. P., Negrotto, S., Smith, N., Terse, P., Engelke, K. J., Covey, J., Chan, K. K., DeSimone, J., & Saunthararajah, Y.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-02-02
- Volume
- 119
- Issue
- 5
- Pages
- 1240-1247
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2113099773
- Cited by
- 99
- References
- 8
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. https://app.cochat.ai/papers/10.1182/blood-2011-08-371690
- The paper
- Lavelle, D., Vaitkus, K., Ling, Y., Ruiz, M. A., Mahfouz, R., Ng, K. P., Negrotto, S., Smith, N., Terse, P., Engelke, K. J., Covey, J., Chan, K. K., DeSimone, J., & Saunthararajah, Y. (2012). Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood. https://doi.org/10.1182/blood-2011-08-371690
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.